3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Breast Neoplasms
66
Neoplasm Metastasis
14
Brain Neoplasms
10
Neoplasms
9
Endometrial Neoplasms
9
Prostatic Neoplasms
7
Glioblastoma
7
Ovarian Neoplasms
6
Triple Negative Breast Neoplasms
5
Glioma
5
Sarcoma
4
Recurrence
3
Neoplasms by Site
3
Meningioma
3
Carcinoma, Non-Small-Cell Lung
3
Breast Diseases
3
Unilateral Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma, Ewing
2
Osteosarcoma
2
Liposarcoma
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Ependymoma
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Advanced Breast Cancer
2
Venous Thromboembolism
1
Uterine Cervical Neoplasms
1
Interventions
Carboplatin
5
pembrolizumab
3
Paclitaxel
3
Observation
3
Capecitabine
3
Azacitidine
3
venetoclax
2
pertuzumab
2
olaparib
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Oxaliplatin
2
Irinotecan
2
Immunotherapy
2
Chemoradiotherapy
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
taxane
1
talazoparib
1
tagraxofusp
1
sarilumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
abemaciclib
×
1 year
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled